MAX-40279-01

MAX-40279-01 is an orally bioavailable, small molecule multi-kinase inhibitor developed by Beijing Zaiji Pharmaceutical. It primarily targets FMS-like tyrosine kinase 3 (FLT3) and the fibroblast growth factor receptor (FGFR) family (FGFR1-4). By dual inhibition of FLT3 and FGFR, the compound is designed to address resistance mechanisms in acute myeloid leukemia (AML), as FGFR signaling is a known escape pathway for FLT3-mutated cells treated with selective FLT3 inhibitors. MAX-40279-01 is currently being investigated in Phase II clinical trials for the treatment of newly diagnosed AML in patients unfit for intensive chemotherapy, often in combination with venetoclax and azacitidine, as well as in relapsed or refractory AML populations.